AVNS — Stock Film
STOCK FILMSCENE 1/11AVNS · $24.61
Stock Expert AI presents
AVNS
Avanos Medical, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Avanos Medical, Inc. A quick introduction.

On the stock market since 2014, it operates in the world of health and science. It has 2,227 employees. Now — the numbers.

on the stock market since 2014
2,227 employees
$1.2B market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.1.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

In the vault right now:
$0
DEBT: $129.1M
At this pace, that money lasts about 1.3 years.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

What executives did with their own stock over the last 12 months:
17 buy15 sell

Executives buying with their own money is usually read as confidence in the company’s future.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
70
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
61
average

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
68
strong

Clearly above the class average — a step short of the very top.

GROWTH
23
very weak

Clearly below the class average.

PRICE MOMENTUM
90
very strong

The stock has been running stronger than the market lately.

WORTH WATCHING

Growth: Sales growth trails the sector average.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking8/10
WEAK SPOTS
Little set aside for the future2/10
Growth has stalled4/10
WORTH WATCHING

R&D Investment: Spending on future research is low.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 36% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/3
Sales are holding up

The company sells $701.2M a year; the problem isn’t sales — it’s costs running above that number.

2
THE BRIGHT SIDE · 2/3
Delivers on expectations

It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.

3
THE BRIGHT SIDE · 3/3
Executives are buying their own stock

Over the last 12 months, company executives reported 17 buys and 15 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/2
The losses continue

A loss of $67.9M against $701.2M in annual sales.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts about 1.3 years. After that, the company needs to find new money.

FINALE · THE GRADE
D
0 / 100 · MoonshotScore

On our five-subject report card, AVNS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: AVNS has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film